U.S. Markets closed

Humanigen, Inc. (HGEN)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
4.9800+0.2800 (+5.96%)
At close: 3:59PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close4.7000
Open4.7000
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range4.6900 - 5.0000
52 Week Range0.3000 - 6.7900
Volume181,233
Avg. Volume472,773
Market Cap629.183M
Beta (5Y Monthly)-1.70
PE Ratio (TTM)N/A
EPS (TTM)-0.0910
Earnings DateAug 11, 2020 - Aug 17, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Humanigen Appoints Bob Atwill as Head of Asia-Pacific Region
    Business Wire

    Humanigen Appoints Bob Atwill as Head of Asia-Pacific Region

    Humanigen, Inc. (HGEN) ("Humanigen"), a clinical stage biopharmaceutical company focused on preventing and treating cytokine release syndrome (CRS) with lenzilumab, the company’s proprietary Humaneered® anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody, today announced the appointment of Bob Atwill, MBA, to the newly created role of Head of Asia-Pacific, effective immediately. Mr. Atwill will report to Dr. Cameron Durrant, Chief Executive Officer of Humanigen, and will initially serve on a consultancy basis.

  • Humanigen to Present at the BTIG Virtual Biotechnology Conference 2020
    Business Wire

    Humanigen to Present at the BTIG Virtual Biotechnology Conference 2020

    Humanigen, Inc., (HGEN) ("Humanigen"), announced today that Cameron Durrant, MD, MBA, Chief Executive Officer and Dale Chappell, MD, MBA, Chief Scientific Officer of Humanigen will present a company overview and business update at the BTIG Virtual Biotechnology Conference 2020 on Tuesday, August 11th, 2020 at 2:00 pm Eastern Time. The conference is being held in a virtual format.

  • ACCESSWIRE

    Humanigen to Host Investor Conference Call to Discuss NIH's Selection of Lenzilumab for Big Effect Trial

    Conference call and webcast scheduled for today, August 3, 2020 at 4:30 pm EDTBURLINGAME, CA / ACCESSWIRE / August 3, 2020 / Humanigen, Inc.